Browsing by Yonsei Author : Kim, Hye Ryun

eperson profile image
Name:
Kim, Hye Ryun [김혜련]
orcid http://orcid.org/0000-0002-1842-9070
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (8583782700)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 192

This table browses all dspace content
Issue DateTitleJournal Title
2023Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing CANCER RESEARCH AND TREATMENT
2023The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer KOREAN JOURNAL OF INTERNAL MEDICINE
2023Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity YONSEI MEDICAL JOURNAL
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study CLINICAL LUNG CANCER
2022YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment FRONTIERS IN CHEMISTRY
2022Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer RADIATION ONCOLOGY
2022Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck RADIATION ONCOLOGY
2022Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes Korean Journal of Otorhinolaryngology-Head and Neck Surgery
2022Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation THERANOSTICS
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2022Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) LUNG CANCER
2022Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials JOURNAL FOR IMMUNOTHERAPY OF CANCER
2022A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors JOURNAL OF THORACIC ONCOLOGY
2022Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice CLINICAL CANCER RESEARCH
2022Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice CURRENT ONCOLOGY
2022Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma CLINICAL AND TRANSLATIONAL MEDICINE
2022Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapyRADIOTHERAPY AND ONCOLOGY
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2022Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell CarcinomaNEW ENGLAND JOURNAL OF MEDICINE
2022SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy IMMUNE NETWORK
2022The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2022Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01) CANCER RESEARCH AND TREATMENT
2022Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01) KOREAN JOURNAL OF INTERNAL MEDICINE
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2021Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck ESMO OPEN
2021Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort JOURNAL OF THORACIC ONCOLOGY
2021Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial JOURNAL OF THORACIC ONCOLOGY
2021Therapeutic Singing as a Swallowing Intervention in Head and Neck Cancer Patients With Dysphagia INTEGRATIVE CANCER THERAPIES
2021두경부암의 최신 표적치료Korean Journal of Head & Neck Oncology(대한두경부종양학회지)
2021Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma JOURNAL OF CLINICAL INVESTIGATION
2021Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer JOURNAL FOR IMMUNOTHERAPY OF CANCER
2021Role and Function of O-GlcNAcylation in Cancer CANCERS
2021Dysregulation of T FH-B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer NATURE COMMUNICATIONS
2021Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations INVESTIGATIONAL NEW DRUGS
2021Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer ANNALS OF ONCOLOGY
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Human reference gut microbiome catalog including newly assembled genomes from under-represented Asian metagenomesGENOME MEDICINE
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2021Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 CANCER RESEARCH AND TREATMENT
2021A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma CANCER MEDICINE
2021Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study CANCERS
2021Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy CANCERS
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2021Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer MOLECULES AND CELLS
2021Clinical Insights Into Novel Immune Checkpoint Inhibitors FRONTIERS IN PHARMACOLOGY
2021Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 JOURNAL OF CLINICAL ONCOLOGY

Browse

Links